<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE book-part-wrapper PUBLIC "-//NLM//DTD BITS Book Interchange DTD v2.0 20151225//EN" "http://jats.nlm.nih.gov/extensions/bits/2.0/BITS-book2.dtd">
<book-part-wrapper id="article-28358" content-type="chapter" dtd-version="2.0">
  <book-meta>
    <book-id book-id-type="pmcid">statpearls</book-id>
    <book-title-group>
      <book-title>StatPearls</book-title>
    </book-title-group>
    <pub-date publication-format="electronic" date-type="pubr">
      <month>01</month>
      <year>2024</year>
    </pub-date>
    <publisher>
      <publisher-name>StatPearls Publishing</publisher-name>
      <publisher-loc>Treasure Island (FL)</publisher-loc>
    </publisher>
    <permissions>
      <copyright-statement>Copyright &#x000a9; 2024, StatPearls Publishing LLC</copyright-statement>
      <license xmlns:xlink="http://www.w3.org/1999/xlink" license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/">
        <license-p>
This book is distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International (CC BY-NC-ND 4.0)
(<ext-link xlink:href="https://creativecommons.org/licenses/by-nc-nd/4.0/" ext-link-type="uri">
http://creativecommons.org/licenses/by-nc-nd/4.0/
</ext-link>), which permits others to distribute the work, provided that the article is not altered or used commercially. You are not required to obtain permission to distribute this article, provided that you credit the author and journal.
</license-p>
      </license>
    </permissions>
    <custom-meta-group>
      <custom-meta>
        <meta-name>books-source-type</meta-name>
        <meta-value>Database</meta-value>
      </custom-meta>
    </custom-meta-group>
    <notes notes-type="disclaimer">
      <p>The intent of StatPearls review books and articles is to identify knowledge deficits and assist you in the learning process. Review books and articles are not intended to be a source of the knowledge base of medicine. The authors and editors do not warrant the information is complete or accurate. The reader is encouraged to verify content and questions in several references. All drug indications and dosages should be verified before administration.</p>
      <p>The authors and editors would like to extend special thanks to Erin Hughes and Gerson Rubio for their editorial support.</p>
    </notes>
  </book-meta>
  <book-part book-part-type="chapter">
    <book-part-meta>
      <title-group>
        <title>Renal Failure Drug Dose Adjustments</title>
      </title-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Kyriakopoulos</surname>
            <given-names>Chris</given-names>
          </name>
          <aff>University Hospital of Ioannina</aff>
        </contrib>
      </contrib-group>
      <contrib-group>
        <contrib contrib-type="author">
          <name name-style="western">
            <surname>Gupta</surname>
            <given-names>Vikas</given-names>
          </name>
          <aff>Wellness Psychiatry P.C</aff>
        </contrib>
      </contrib-group>
      <author-notes>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Chris Kyriakopoulos declares no relevant financial relationships with ineligible companies.</p>
        </fn>
        <fn fn-type="COI-statement">
          <p><bold>Disclosure: </bold>Vikas Gupta declares no relevant financial relationships with ineligible companies.</p>
        </fn>
      </author-notes>
      <pub-history>
        <date date-type="updated">
          <day>27</day>
          <month>7</month>
          <year>2024</year>
        </date>
      </pub-history>
    </book-part-meta>
    <body>
      <sec id="article-28358.s1" sec-type="Definition/Introduction">
        <title>Definition/Introduction</title>
        <p content-type="pubmed-excerpt">The effects of many drugs are altered in renal impairment, particularly when&#x000a0;a drug is renally cleared. Drug doses should be altered based on the predicted reduction in the clearance of the drug. Patient factors, such as the degree of renal disease and patient size, also influence the decision to adjust drug doses.&#x000a0;In addition, drug factors, including the drug excretion and the therapeutic index, must be considered when adjusting doses. Accurate estimation of renal function is crucial for determining appropriate doses of renally excreted drugs.</p>
        <p>Renal disease can alter drug concentrations and effects in the body, occasionally reducing effects but more commonly escalating their effects and thus causing potential toxicity. Most of these changes are predictable and may be prevented by altering drug doses in accordance with established guidelines.</p>
        <p>Renal disease primarily affects drug dosing in 3 ways:</p>
        <list list-type="bullet">
          <list-item>
            <p>Patient susceptibility: Patients with renal&#x000a0;impairment&#x000a0;may be more vulnerable to a&#x000a0;specific drug effect.</p>
          </list-item>
          <list-item>
            <p>Pharmacodynamic change: The effect of a drug&#x000a0;may be increased or decreased in patients with renal disease.</p>
          </list-item>
          <list-item>
            <p>Pharmacokinetic changes: When given at usual doses, some drugs have higher steady-state concentrations in patients with renal&#x000a0;impairment.</p>
          </list-item>
        </list>
        <p>Chronic kidney disease&#x000a0;(CKD) is a type of kidney disorder characterized by a gradual decline in kidney function that occurs over several months to years.<xref ref-type="bibr" rid="article-28358.r1">[1]</xref>&#x000a0;Although various organs contribute to drug metabolism and excretion, the liver is the primary site for metabolism, and the kidneys are primarily responsible for excretion.</p>
        <p>CKD is defined as a glomerular filtration rate (GFR) lower than 60 mL/min or albumin higher than 30 mg/g of creatinine, accompanied by abnormalities of kidney structure or function for more than 3 months.&#x000a0;End-stage renal&#x000a0;disease is a GFR of less than 15 mL/min.</p>
        <p>Renal impairment modifies the effects of many medications, occasionally diminishing them but more typically enhancing or even multiplying them, thus leading to accumulation and potential toxicity. Many of these alterations can be and should be predicted and subsequently alleviated by adjusting drug doses.</p>
        <p>In summary, the medication dose should be decreased equivalently to the calculated reduction of drug clearance.</p>
      </sec>
      <sec id="article-28358.s2" sec-type="Issues of Concern">
        <title>Issues of Concern</title>
        <p>CKD is classified into 6 stages. Determining whether a patient has renal insufficiency (CKD stages 2 through 5) and identifying the specific stage are crucial&#x000a0;because the kidneys excrete almost half of all drugs or their metabolites, and 30% of all adverse effects of medication are attributed to either a renal cause or a renal effect.<xref ref-type="bibr" rid="article-28358.r2">[2]</xref> CKD affects a significant proportion of the general population, especially hospitalized patients.&#x000a0;According to the NHANES study, the prevalence of renal insufficiency with a GFR below 60 mL/min is 11% to 13%, and&#x000a0;about&#x000a0;20% of hospitalized patients have impaired renal function.<xref ref-type="bibr" rid="article-28358.r3">[3]</xref></p>
        <p>In patients with renal impairment, the dosing of renally cleared drugs has to be adjusted based on the patient's actual GFR. In the past, this adjustment was&#x000a0;made using the Cockcroft-Gault equation or by measuring creatinine clearance.<xref ref-type="bibr" rid="article-28358.r4">[4]</xref>&#x000a0;Previously, the Modification of Diet in Renal Disease (MDRD) formula was also used. However, the Chronic Kidney Disease-Epidemiology Collaborative Group (CKD-EPI) creatinine-based formula has largely replaced these older methods.</p>
        <p>The CKD-EPI task force has also developed complex equations incorporating serum creatinine and cystatin C, using a population comprising healthy individuals and CKD patients, which are preferred when estimating GFRs in multi-ethnic populations due to their reduced bias.<xref ref-type="bibr" rid="article-28358.r5">[5]</xref>&#x000a0;A recent review by Inker et al presented new equations using cystatin C and creatinine without race,&#x000a0;demonstrating an improved correlation between measured and calculated GFR. These complex equations can be found in this study and supplementary materials.<xref ref-type="bibr" rid="article-28358.r6">[6]</xref>&#x000a0;</p>
        <p>The use of race as a qualitative factor to estimate muscle mass was previously supported, but the trend is toward removing race from GFR calculations. The current CKD-EPI formulas have gone through several iterations.&#x000a0;Although some experts may prefer eGFR equations using cystatin or both cystatin and creatinine, in practice, cystatin is not widely measured. Therefore, the National Kidney Foundation (NKF) and the American Society of Nephrology (ASN) Task Force recommend using the CKD-EPI creatinine-based equation.<xref ref-type="bibr" rid="article-28358.r7">[7]</xref>&#x000a0;This formula uses serum creatinine, age, and constant values. For estimated GFR,&#x000a0;this formula has been adopted by most major laboratories, including national laboratories.</p>
        <p>The GFR is estimated using various formulas, and it is calculated as follows:</p>
        <list list-type="bullet">
          <list-item>
            <p>The Cockroft-Gault formula</p>
          </list-item>
        </list>
        <p>GFR = [(140&#x02212;age) &#x000d7; weight]/[(72 &#x000d7; SCr) &#x000d7; 0.85 (if female)]</p>
        <list list-type="bullet">
          <list-item>
            <p>The MDRD equation&#x000a0;</p>
          </list-item>
        </list>
        <p>186 &#x000d7; (SCr/88.4) &#x000d7; (Age) &#x000d7; (0.742 if female) &#x000d7; (1.210 if black)</p>
        <list list-type="bullet">
          <list-item>
            <p>CKD-EPI equation</p>
          </list-item>
        </list>
        <p>eGFR = 142 &#x000d7; min(SCr/<italic toggle="yes">&#x003ba;</italic>,1)<italic toggle="yes"><sup>&#x003b1;</sup></italic>&#x000a0;&#x000d7; max(SCr/<italic toggle="yes">&#x003ba;</italic>,1)<sup>&#x02212;1.200</sup> &#x000d7; 0.9938<sup>Age</sup> &#x000d7; 1.012 (if female)</p>
        <p>Abbreviations/unitsSCr is serum creatinine in mg/dL<italic toggle="yes">&#x003ba;</italic> = 0.7 for females and 0.9 for males<italic toggle="yes">&#x003b1;</italic> = &#x02212;0.329 for females and &#x02212;0.411 for malesmin = the minimum of S/<italic toggle="yes">&#x003ba;</italic> or 1, andmax = the maximum of S/<italic toggle="yes">&#x003ba;</italic> or 1</p>
        <p>
<bold>Classification of CKD Based on GFR</bold>
</p>
        <list list-type="bullet">
          <list-item>
            <p>Stage 1: GFR&#x000a0;120&#x000a0;to 90 mL/min (GFR is normal, but mild abnormalities, such as proteinuria, indicate possible underlying renal pathology)</p>
          </list-item>
          <list-item>
            <p>Stage&#x000a0;2: GFR&#x000a0;89&#x000a0;to 60 mL/min (mild renal insufficiency)</p>
          </list-item>
          <list-item>
            <p>Stage&#x000a0;3a: GFR&#x000a0;59&#x000a0;to 45 mL/min (intermediate&#x000a0;renal insufficiency)</p>
          </list-item>
          <list-item>
            <p>Stage&#x000a0;3b: GFR&#x000a0;44&#x000a0;to 30 mL/min (moderate&#x000a0;renal insufficiency)</p>
          </list-item>
          <list-item>
            <p>Stage&#x000a0;4: GFR&#x000a0;29&#x000a0;to 15 mL/min (severe&#x000a0;renal insufficiency)</p>
          </list-item>
          <list-item>
            <p>Stage&#x000a0;5: GFR&#x000a0;14&#x000a0;to 0 mL/min (preterminal, requires renal replacement therapy)</p>
          </list-item>
        </list>
        <p>The units of drug dosing are typically expressed as the amount of drug administered per unit of time. Dose adjustment is&#x000a0;typically crude for most drugs in many circumstances,&#x000a0;such as&#x000a0;doubling or halving doses. In most cases, having the means to&#x000a0;establish when the drug dose should be doubled or halved is crucial, whereas a 20%&#x000a0;alteration in dose is typically impractical and unnecessary. However, there are many drugs for which minor changes in dose or concentration may&#x000a0;cause a significant&#x000a0;effect, commonly&#x000a0;called a narrow therapeutic index. The therapeutic index is calculated using the following formula:</p>
        <list list-type="bullet">
          <list-item>
            <p>The therapeutic index = minimum toxic dose / minimum effective dose</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28358.s3" sec-type="Clinical Significance">
        <title>Clinical Significance</title>
        <p>Factors and conditions that may worsen the renal injury and thus should be either avoided or resolved include the following:</p>
        <list list-type="bullet">
          <list-item>
            <p>Nephrotoxic drugs, such as nonsteroidal anti-inflammatory drugs, aminoglycosides, and iodinated contrast</p>
          </list-item>
          <list-item>
            <p>Uncontrolled diabetes</p>
          </list-item>
          <list-item>
            <p>Systemic hypertension</p>
          </list-item>
          <list-item>
            <p>Proteinuria</p>
          </list-item>
          <list-item>
            <p>Dehydration</p>
          </list-item>
          <list-item>
            <p>Smoking</p>
          </list-item>
          <list-item>
            <p>Hyperlipidemia</p>
          </list-item>
          <list-item>
            <p>Hyperphosphatemia</p>
          </list-item>
        </list>
      </sec>
      <sec id="article-28358.s4" sec-type="Nursing, Allied Health, and Interprofessional Team Interventions">
        <title>Nursing, Allied Health, and Interprofessional Team Interventions</title>
        <p>Based on several studies, 34% to 53% of the drugs requiring adjustment were not considered in physicians' instructions.<xref ref-type="bibr" rid="article-28358.r8">[8]</xref><xref ref-type="bibr" rid="article-28358.r9">[9]</xref> There are various explanations for the inadequacy of medication dose regulation. The most frequent reason is that physicians often underestimate the impact of mild and intermediate renal insufficiency or that they have inadequate knowledge of the medications that require dose adjustment in renal insufficiency. Although the serum creatinine&#x000a0;level is a widely used value in everyday practice, this is a late biomarker of decreased renal function (rising only after significant loss of renal function), thus leading to underestimating renal impairment, especially among older patients.</p>
        <p>Another possible explanation is that physicians do not calculate the creatinine clearance using one of the three existing formulas due to insufficient time, which leads to underestimating the necessity of adjusting&#x000a0;medication dosage.<xref ref-type="bibr" rid="article-28358.r10">[10]</xref>&#x000a0;The Food and Drug Administration and European Medicines Agency&#x000a0;have particular guidelines about pharmacokinetics regarding patients with impaired renal function that should be followed when developing new drugs.<xref ref-type="bibr" rid="article-28358.r11">[11]</xref><xref ref-type="bibr" rid="article-28358.r12">[12]</xref>&#x000a0;Physicians should consider the potential adverse effects, drug interactions, and treatment failures or discontinuations due to nephrotoxicity before administering any drug.</p>
        <p>Effective communication between physicians, pharmacists, and nurses is essential for safe and appropriate drug administration in patients with renal impairment.</p>
      </sec>
      <sec id="article-28358.s5">
        <title>Review Questions</title>
        <list list-type="bullet">
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/account/trialuserreg/?articleid=28358&#x00026;utm_source=pubmed&#x00026;utm_campaign=reviews&#x00026;utm_content=28358">Access free multiple choice questions on this topic.</ext-link>
</p>
          </list-item>
          <list-item>
            <p>
<ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://www.statpearls.com/articlelibrary/commentarticle/28358/?utm_source=pubmed&#x00026;utm_campaign=comments&#x00026;utm_content=28358">Comment on this article.</ext-link>
</p>
          </list-item>
        </list>
      </sec>
    </body>
    <back>
      <ref-list id="article-28358.s6">
        <title>References</title>
        <ref id="article-28358.r1">
          <label>1</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Stevens</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Nolin</surname>
                <given-names>TD</given-names>
              </name>
              <name>
                <surname>Richardson</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Lewis</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Rodby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Townsend</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Okparavero</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <collab>Chronic Kidney Disease Epidemiology Collaboration</collab>
            </person-group>
            <article-title>Comparison of drug dosing recommendations based on measured GFR and kidney function estimating equations.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2009</year>
            <month>Jul</month>
            <volume>54</volume>
            <issue>1</issue>
            <fpage>33</fpage>
            <page-range>33-42</page-range>
            <pub-id pub-id-type="pmid">19446939</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r2">
          <label>2</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Lattanzio</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Corsonello</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Montesanto</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Abbatecola</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Lofaro</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Passarino</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Fusco</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Corica</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Pedone</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Maggio</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Volpato</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Incalzi</surname>
                <given-names>RA</given-names>
              </name>
            </person-group>
            <article-title>Disentangling the Impact of Chronic Kidney Disease, Anemia, and Mobility Limitation on Mortality in Older Patients Discharged From Hospital.</article-title>
            <source>J Gerontol A Biol Sci Med Sci</source>
            <year>2015</year>
            <month>Sep</month>
            <volume>70</volume>
            <issue>9</issue>
            <fpage>1120</fpage>
            <page-range>1120-7</page-range>
            <pub-id pub-id-type="pmid">25991829</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r3">
          <label>3</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Stevens</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Schmid</surname>
                <given-names>CH</given-names>
              </name>
              <name>
                <surname>Zhang</surname>
                <given-names>YL</given-names>
              </name>
              <name>
                <surname>Castro</surname>
                <given-names>AF</given-names>
              </name>
              <name>
                <surname>Feldman</surname>
                <given-names>HI</given-names>
              </name>
              <name>
                <surname>Kusek</surname>
                <given-names>JW</given-names>
              </name>
              <name>
                <surname>Eggers</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Van Lente</surname>
                <given-names>F</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Coresh</surname>
                <given-names>J</given-names>
              </name>
              <collab>CKD-EPI (Chronic Kidney Disease Epidemiology Collaboration)</collab>
            </person-group>
            <article-title>A new equation to estimate glomerular filtration rate.</article-title>
            <source>Ann Intern Med</source>
            <year>2009</year>
            <month>May</month>
            <day>05</day>
            <volume>150</volume>
            <issue>9</issue>
            <fpage>604</fpage>
            <page-range>604-12</page-range>
            <pub-id pub-id-type="pmid">19414839</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r4">
          <label>4</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Cockcroft</surname>
                <given-names>DW</given-names>
              </name>
              <name>
                <surname>Gault</surname>
                <given-names>MH</given-names>
              </name>
            </person-group>
            <article-title>Prediction of creatinine clearance from serum creatinine.</article-title>
            <source>Nephron</source>
            <year>1976</year>
            <volume>16</volume>
            <issue>1</issue>
            <fpage>31</fpage>
            <page-range>31-41</page-range>
            <pub-id pub-id-type="pmid">1244564</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r5">
          <label>5</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Hundemer</surname>
                <given-names>GL</given-names>
              </name>
              <name>
                <surname>White</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Norman</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Knoll</surname>
                <given-names>GA</given-names>
              </name>
              <name>
                <surname>Tangri</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Sood</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Hiremath</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Burns</surname>
                <given-names>KD</given-names>
              </name>
              <name>
                <surname>McCudden</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Akbari</surname>
                <given-names>A</given-names>
              </name>
            </person-group>
            <article-title>Performance of the 2021 Race-Free CKD-EPI Creatinine-&#x000a0;and Cystatin C-Based Estimated GFR Equations Among Kidney Transplant Recipients.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Oct</month>
            <volume>80</volume>
            <issue>4</issue>
            <fpage>462</fpage>
            <page-range>462-472.e1</page-range>
            <pub-id pub-id-type="pmid">35588905</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r6">
          <label>6</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Inker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Eneanya</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Coresh</surname>
                <given-names>J</given-names>
              </name>
              <name>
                <surname>Tighiouart</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wang</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>Sang</surname>
                <given-names>Y</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Doria</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Estrella</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Froissart</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Grams</surname>
                <given-names>ME</given-names>
              </name>
              <name>
                <surname>Greene</surname>
                <given-names>T</given-names>
              </name>
              <name>
                <surname>Grubb</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Gudnason</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Guti&#x000e9;rrez</surname>
                <given-names>OM</given-names>
              </name>
              <name>
                <surname>Kalil</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Karger</surname>
                <given-names>AB</given-names>
              </name>
              <name>
                <surname>Mauer</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Navis</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Nelson</surname>
                <given-names>RG</given-names>
              </name>
              <name>
                <surname>Poggio</surname>
                <given-names>ED</given-names>
              </name>
              <name>
                <surname>Rodby</surname>
                <given-names>R</given-names>
              </name>
              <name>
                <surname>Rossing</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Rule</surname>
                <given-names>AD</given-names>
              </name>
              <name>
                <surname>Selvin</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Seegmiller</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Shlipak</surname>
                <given-names>MG</given-names>
              </name>
              <name>
                <surname>Torres</surname>
                <given-names>VE</given-names>
              </name>
              <name>
                <surname>Yang</surname>
                <given-names>W</given-names>
              </name>
              <name>
                <surname>Ballew</surname>
                <given-names>SH</given-names>
              </name>
              <name>
                <surname>Couture</surname>
                <given-names>SJ</given-names>
              </name>
              <name>
                <surname>Powe</surname>
                <given-names>NR</given-names>
              </name>
              <name>
                <surname>Levey</surname>
                <given-names>AS</given-names>
              </name>
              <collab>Chronic Kidney Disease Epidemiology Collaboration</collab>
            </person-group>
            <article-title>New Creatinine- and Cystatin C-Based Equations to Estimate GFR without Race.</article-title>
            <source>N Engl J Med</source>
            <year>2021</year>
            <month>Nov</month>
            <day>04</day>
            <volume>385</volume>
            <issue>19</issue>
            <fpage>1737</fpage>
            <page-range>1737-1749</page-range>
            <pub-id pub-id-type="pmid">34554658</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r7">
          <label>7</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Delgado</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Baweja</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Crews</surname>
                <given-names>DC</given-names>
              </name>
              <name>
                <surname>Eneanya</surname>
                <given-names>ND</given-names>
              </name>
              <name>
                <surname>Gadegbeku</surname>
                <given-names>CA</given-names>
              </name>
              <name>
                <surname>Inker</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Mendu</surname>
                <given-names>ML</given-names>
              </name>
              <name>
                <surname>Miller</surname>
                <given-names>WG</given-names>
              </name>
              <name>
                <surname>Moxey-Mims</surname>
                <given-names>MM</given-names>
              </name>
              <name>
                <surname>Roberts</surname>
                <given-names>GV</given-names>
              </name>
              <name>
                <surname>St Peter</surname>
                <given-names>WL</given-names>
              </name>
              <name>
                <surname>Warfield</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Powe</surname>
                <given-names>NR</given-names>
              </name>
            </person-group>
            <article-title>A Unifying Approach for GFR Estimation: Recommendations of the NKF-ASN Task Force on Reassessing the Inclusion of Race in Diagnosing Kidney Disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2022</year>
            <month>Feb</month>
            <volume>79</volume>
            <issue>2</issue>
            <fpage>268</fpage>
            <page-range>268-288.e1</page-range>
            <pub-id pub-id-type="pmid">34563581</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r8">
          <label>8</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Alahdal</surname>
                <given-names>AM</given-names>
              </name>
              <name>
                <surname>Elberry</surname>
                <given-names>AA</given-names>
              </name>
            </person-group>
            <article-title>Evaluation of applying drug dose adjustment by physicians in patients with renal impairment.</article-title>
            <source>Saudi Pharm J</source>
            <year>2012</year>
            <month>Jul</month>
            <volume>20</volume>
            <issue>3</issue>
            <fpage>217</fpage>
            <page-range>217-20</page-range>
            <pub-id pub-id-type="pmid">23960796</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r9">
          <label>9</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Salomon</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Deray</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Jaudon</surname>
                <given-names>MC</given-names>
              </name>
              <name>
                <surname>Chebassier</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Bossi</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Launay-Vacher</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Diquet</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Ceza</surname>
                <given-names>JM</given-names>
              </name>
              <name>
                <surname>Levu</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Br&#x000fc;cker</surname>
                <given-names>G</given-names>
              </name>
              <name>
                <surname>Ravaud</surname>
                <given-names>P</given-names>
              </name>
            </person-group>
            <article-title>Medication misuse in hospitalized patients with renal impairment.</article-title>
            <source>Int J Qual Health Care</source>
            <year>2003</year>
            <month>Aug</month>
            <volume>15</volume>
            <issue>4</issue>
            <fpage>331</fpage>
            <page-range>331-5</page-range>
            <pub-id pub-id-type="pmid">12930048</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r10">
          <label>10</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Mariani</surname>
                <given-names>LH</given-names>
              </name>
              <name>
                <surname>Bomback</surname>
                <given-names>AS</given-names>
              </name>
              <name>
                <surname>Canetta</surname>
                <given-names>PA</given-names>
              </name>
              <name>
                <surname>Flessner</surname>
                <given-names>MF</given-names>
              </name>
              <name>
                <surname>Helmuth</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Hladunewich</surname>
                <given-names>MA</given-names>
              </name>
              <name>
                <surname>Hogan</surname>
                <given-names>JJ</given-names>
              </name>
              <name>
                <surname>Kiryluk</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Nachman</surname>
                <given-names>PH</given-names>
              </name>
              <name>
                <surname>Nast</surname>
                <given-names>CC</given-names>
              </name>
              <name>
                <surname>Rheault</surname>
                <given-names>MN</given-names>
              </name>
              <name>
                <surname>Rizk</surname>
                <given-names>DV</given-names>
              </name>
              <name>
                <surname>Trachtman</surname>
                <given-names>H</given-names>
              </name>
              <name>
                <surname>Wenderfer</surname>
                <given-names>SE</given-names>
              </name>
              <name>
                <surname>Bowers</surname>
                <given-names>C</given-names>
              </name>
              <name>
                <surname>Hill-Callahan</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Marasa</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Poulton</surname>
                <given-names>CJ</given-names>
              </name>
              <name>
                <surname>Revell</surname>
                <given-names>A</given-names>
              </name>
              <name>
                <surname>Vento</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Barisoni</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Cattran</surname>
                <given-names>D</given-names>
              </name>
              <name>
                <surname>D'Agati</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Jennette</surname>
                <given-names>JC</given-names>
              </name>
              <name>
                <surname>Klein</surname>
                <given-names>JB</given-names>
              </name>
              <name>
                <surname>Laurin</surname>
                <given-names>LP</given-names>
              </name>
              <name>
                <surname>Twombley</surname>
                <given-names>K</given-names>
              </name>
              <name>
                <surname>Falk</surname>
                <given-names>RJ</given-names>
              </name>
              <name>
                <surname>Gharavi</surname>
                <given-names>AG</given-names>
              </name>
              <name>
                <surname>Gillespie</surname>
                <given-names>BW</given-names>
              </name>
              <name>
                <surname>Gipson</surname>
                <given-names>DS</given-names>
              </name>
              <name>
                <surname>Greenbaum</surname>
                <given-names>LA</given-names>
              </name>
              <name>
                <surname>Holzman</surname>
                <given-names>LB</given-names>
              </name>
              <name>
                <surname>Kretzler</surname>
                <given-names>M</given-names>
              </name>
              <name>
                <surname>Robinson</surname>
                <given-names>B</given-names>
              </name>
              <name>
                <surname>Smoyer</surname>
                <given-names>WE</given-names>
              </name>
              <name>
                <surname>Guay-Woodford</surname>
                <given-names>LM</given-names>
              </name>
              <collab>CureGN Consortium</collab>
            </person-group>
            <article-title>CureGN Study Rationale, Design, and Methods: Establishing a Large Prospective Observational Study of Glomerular Disease.</article-title>
            <source>Am J Kidney Dis</source>
            <year>2019</year>
            <month>Feb</month>
            <volume>73</volume>
            <issue>2</issue>
            <fpage>218</fpage>
            <page-range>218-229</page-range>
            <pub-id pub-id-type="pmid">30420158</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r11">
          <label>11</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Paglialunga</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Offman</surname>
                <given-names>E</given-names>
              </name>
              <name>
                <surname>Ichhpurani</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Marbury</surname>
                <given-names>TC</given-names>
              </name>
              <name>
                <surname>Morimoto</surname>
                <given-names>BH</given-names>
              </name>
            </person-group>
            <article-title>Update and trends on pharmacokinetic studies in patients with impaired renal function: practical insight into application of the FDA and EMA guidelines.</article-title>
            <source>Expert Rev Clin Pharmacol</source>
            <year>2017</year>
            <month>Mar</month>
            <volume>10</volume>
            <issue>3</issue>
            <fpage>273</fpage>
            <page-range>273-283</page-range>
            <pub-id pub-id-type="pmid">27998190</pub-id>
          </element-citation>
        </ref>
        <ref id="article-28358.r12">
          <label>12</label>
          <element-citation publication-type="journal">
            <person-group>
              <name>
                <surname>Zhang</surname>
                <given-names>L</given-names>
              </name>
              <name>
                <surname>Xu</surname>
                <given-names>N</given-names>
              </name>
              <name>
                <surname>Xiao</surname>
                <given-names>S</given-names>
              </name>
              <name>
                <surname>Arya</surname>
                <given-names>V</given-names>
              </name>
              <name>
                <surname>Zhao</surname>
                <given-names>P</given-names>
              </name>
              <name>
                <surname>Lesko</surname>
                <given-names>LJ</given-names>
              </name>
              <name>
                <surname>Huang</surname>
                <given-names>SM</given-names>
              </name>
            </person-group>
            <article-title>Regulatory perspectives on designing pharmacokinetic studies and optimizing labeling recommendations for patients with chronic kidney disease.</article-title>
            <source>J Clin Pharmacol</source>
            <year>2012</year>
            <month>Jan</month>
            <volume>52</volume>
            <issue>1 Suppl</issue>
            <fpage>79S</fpage>
            <page-range>79S-90S</page-range>
            <pub-id pub-id-type="pmid">22232757</pub-id>
          </element-citation>
        </ref>
      </ref-list>
    </back>
  </book-part>
</book-part-wrapper>
